RNS REACH: RELEASE                                                                                                                                 24 June 2026

ImmuPharma PLC

("ImmuPharma" or the "Company")

University of Murcia research relating to P140

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes the recent article published in the scientific journal Autophagy, which reports early-stage research conducted by the University of Murcia ("UoM") relating to the P140 peptide and its potential application in glioblastoma, an aggressive form of brain cancer.

ImmuPharma acknowledges the quality of the scientific work conducted by the UoM in this area and confirms that it has been aware of, and has followed, this research since 2024 and is in regular contact with the research team at UoM. These findings are supportive of ImmuPharma's broader scientific work on P140 and are consistent with the scientific rationale underlying the program.

P140 remains ImmuPharma's lead asset, and the Company's primary focus continues to be the advancement of P140 in autoimmune disease.

Further updates will be provided to the market when appropriate.

Ends

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk.

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.